Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Eribulin in Triple-Negative Breast Cancer
NCT02616848Phase 1Unknown
- Sponsor
- ASST Cremona
- Start
- Nov 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of everolimus in triple-negative breast cancer (TNBC), sponsored by ASST Cremona. Primary endpoint: Recommended dose of everolimus in combination with eribulin at 6 months. Status: unknown.
02
Drugs
everolimus
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02616848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02616848.